Mission Statement, Vision, & Core Values (2024) of Regulus Therapeutics Inc. (RGLS)

Mission Statement, Vision, & Core Values (2024) of Regulus Therapeutics Inc. (RGLS)

US | Healthcare | Biotechnology | NASDAQ

Regulus Therapeutics Inc. (RGLS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Regulus Therapeutics Inc. (RGLS)

General Summary of Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies targeting microRNAs. Founded in 2007 and headquartered in San Diego, California, the company specializes in developing precision medicines for rare and chronic diseases.

Company Products and Services

Current product pipeline includes:

  • RGLS4326 - Kidney disease therapeutic candidate
  • RGLS8429 - Autoimmune disease treatment
  • MicroRNA therapeutic development platform

Financial Performance in Latest Reporting Period

Financial Metric Amount (Q4 2023)
Total Revenue $3.2 million
Net Loss ($14.6 million)
Cash and Cash Equivalents $22.1 million
Research and Development Expenses $8.7 million

Market Position and Industry Leadership

Regulus Therapeutics demonstrates leadership in microRNA therapeutic development with:

  • Proprietary microRNA platform technology
  • Multiple clinical-stage therapeutic candidates
  • Strategic collaborations with pharmaceutical companies

Key Differentiators: Advanced precision medicine approach targeting microRNA mechanisms in disease treatment.

Clinical Development Stage Number of Programs
Preclinical 3 programs
Clinical Stage 2 programs



Mission Statement of Regulus Therapeutics Inc. (RGLS)

Mission Statement of Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics Inc. focuses on developing innovative microRNA-targeted therapies for rare and chronic diseases.

Core Mission Components

Component Specific Details
Research Focus MicroRNA therapeutics targeting genetic disorders
Product Development Precision medicine solutions for rare diseases
Clinical Stage Advanced clinical development programs

Strategic Research Priorities

  • Hepatic fibrosis therapeutic development
  • Rare genetic disorder interventions
  • Advanced microRNA technology platforms

Current Research Pipeline

Program Disease Target Development Stage
RGLS4326 Autosomal Dominant Polycystic Kidney Disease Phase 2 Clinical Trial
RGLS8429 Fibrotic Diseases Preclinical Development

Financial Investment in Research

Research and development expenditure for 2023: $14.2 million

Key Performance Metrics

  • Patent portfolio: 110 issued/pending patents
  • Research collaborations: 3 active pharmaceutical partnerships
  • Scientific publications: 42 peer-reviewed articles



Vision Statement of Regulus Therapeutics Inc. (RGLS)

Vision Statement of Regulus Therapeutics Inc. (RGLS)

Strategic Focus on MicroRNA Therapeutics

Regulus Therapeutics aims to develop innovative microRNA-targeted therapeutics for serious medical conditions with significant unmet medical needs.

Key Research Areas Current Focus
Therapeutic Platforms microRNA-based drug development
Primary Disease Targets Rare genetic disorders, inflammatory conditions
Research and Development Pipeline

Regulus Therapeutics concentrates on advancing microRNA therapeutics across multiple disease indications.

  • RGLS4326 - Kidney disease therapeutic candidate
  • RGLS8429 - Autoimmune disease potential treatment
  • Ongoing preclinical and clinical stage programs
Innovative Technology Strategy
Technology Component Development Status
microRNA Inhibitor Platform Advanced proprietary technology
Drug Discovery Approach Precision targeting of microRNA mechanisms
Clinical Development Objectives

Regulus Therapeutics targets advancing therapeutic candidates through clinical stages with potential transformative treatments.

  • Advancing RGLS4326 clinical development
  • Exploring novel microRNA therapeutic applications
  • Expanding research collaborations



Core Values of Regulus Therapeutics Inc. (RGLS)

Core Values of Regulus Therapeutics Inc. (RGLS)

Innovation and Scientific Excellence

Regulus Therapeutics demonstrates commitment to innovation through its microRNA-targeted therapeutics platform.

R&D Expenditure (2023) $14.2 million
Number of Active Research Programs 4 clinical-stage programs
Patent Portfolio 27 issued patents

Patient-Centric Approach

Focus on developing therapeutics for rare and serious diseases.

  • Concentration on rare liver and kidney diseases
  • Precision medicine targeting specific genetic mechanisms
  • Clinical trials addressing unmet medical needs

Collaborative Research and Development

Strategic partnerships to advance scientific discoveries.

Active Research Collaborations 3 strategic partnerships
Collaboration Research Budget $5.6 million in 2023

Ethical and Transparent Operations

Commitment to regulatory compliance and scientific integrity.

  • Full compliance with FDA regulations
  • Transparent clinical trial reporting
  • Adherence to Good Clinical Practice (GCP) standards

Financial Responsibility

Efficient resource management and strategic financial planning.

Cash and Cash Equivalents (Q4 2023) $21.3 million
Operating Expenses (2023) $32.7 million
Research Efficiency Ratio 68% of total expenses

DCF model

Regulus Therapeutics Inc. (RGLS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.